Bellicum today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $7.50 per share.
LivaNova announced it received CE Mark for its Vagus Nerve Stimulation Therapy® System comprised of the SenTiva® generator and next-generation Programming System.
Bellicum today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock.
Bellicum today announced that the U.S. Food and Drug Administration has lifted the clinical hold on studies of BPX-501 in the U.S.
Moleculin today announced that patients have successfully begun treatment in its U.S. Phase I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (“AML”).
LivaNova has received CE Mark approval for its Bicarbon® aortic valves for use with low-dose anticoagulant therapy.
LivaNova today announced the launch and enrollment of the first patient in a clinical study to examine the use of LivaNova’s new Microburst Vagus Nerve Stimulation Therapy® (“VNS Therapy”) System.
Moleculin today announced that it has partnered with The University Hospitals Cleveland Medical Center to participate in its U.S. Phase I/II clinical trial of Annamycin.